tetano
Editor, Senior Moderator
J Infect
. 2022 Jun 16;S0163-4453(22)00361-9.
doi: 10.1016/j.jinf.2022.06.009. Online ahead of print.
Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults
Rajeka Lazarus[SUP] 1 [/SUP], Christian Taucher[SUP] 2 [/SUP], Claire Brown[SUP] 3 [/SUP], Irena Corbic[SUP] 4 [/SUP], Leon Danon[SUP] 5 [/SUP], Katrin Dubischar[SUP] 4 [/SUP], Christopher J A Duncan[SUP] 6 [/SUP], Susanne Eder-Lingelbach[SUP] 4 [/SUP], Saul N Faust[SUP] 7 [/SUP], Christopher Green[SUP] 3 [/SUP], Karishma Gokani[SUP] 3 [/SUP], Romana Hochreiter[SUP] 4 [/SUP], Johanna Kellett Wright[SUP] 1 [/SUP], Dowan Kwon[SUP] 1 [/SUP], Alexander Middleditch[SUP] 1 [/SUP], Alasdair P S Munro[SUP] 7 [/SUP], Kush Naker[SUP] 3 [/SUP], Florentina Penciu[SUP] 1 [/SUP], David Price[SUP] 6 [/SUP], Benedicte Querton[SUP] 4 [/SUP], Tawassal Riaz[SUP] 1 [/SUP], Amy Ross-Russell[SUP] 7 [/SUP], Amada Sanchez-Gonzalez[SUP] 6 [/SUP], Hayley Wardle[SUP] 6 [/SUP], Sarah Warren[SUP] 7 [/SUP], Adam Finn[SUP] 8 [/SUP], Valneva Phase 1 Trial Group
Affiliations
Abstract
Objectives: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001.
Methods: We conducted an open-label, dose-escalation study followed by a double-blind randomized trial using low, medium and high doses of VLA2001 (1:1:1). The primary safety outcome was the frequency and severity of solicited local and systemic reactions within 7 days after vaccination. The primary immunogenicity outcome was the geometric mean titre of (GMT) of neutralizing antibodies against SARS-CoV-2 two weeks after the second vaccination. The study is registered as NCT04671017.
Results: Between December 16, 2020, and June 3, 2021, 153 healthy adults aged 18-55 years were recruited in the UK. Overall, 81.7% of the participants reported a solicited AE, with injection site tenderness (58.2%) and headache (46.4%) being the most frequent. Only 2 participants reported a severe solicited event. Up to day 106, 131 (85.6%) participants had reported any AE. All observed incidents were transient and non-life threatening in nature. Immunogenicity measured at 2 weeks after completion of the two-dose priming schedule, showed significantly higher GMTs of SARS-CoV-2 neutralising antibody titres in the highest dose group (GMT 545.6; 95% CI: 428.1, 695.4) which were similar to a panel of convalescent sera (GMT 526.9; 95% CI: 336.47, 825.06). Seroconversion rates of neutralising antibodies were also significantly higher in the high-dose group (>90%) compared to the other dose groups. In the high dose group, antigen-specific interferon-γ expressing T-cells reactive against the S, M and N proteins were observed in 76, 36 and 49%, respectively.
Conclusions: VLA2001 was well tolerated in all tested dose groups, and no safety signal of concern was identified. The highest dose group showed statistically significantly stronger immunogenicity with similar tolerability and safety, and was selected for phase 3 clinical development.
Keywords: COVID-19; Coronavirus; CpG 1018; RBD-binding IgG antibody; S protein binding IgG antibody; SARS-CoV-2; adjuvanted vaccine; aluminum hydroxide; inactivated vaccine; neutralizing antibody; vaccine safety; whole-virus vaccine.
. 2022 Jun 16;S0163-4453(22)00361-9.
doi: 10.1016/j.jinf.2022.06.009. Online ahead of print.
Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults
Rajeka Lazarus[SUP] 1 [/SUP], Christian Taucher[SUP] 2 [/SUP], Claire Brown[SUP] 3 [/SUP], Irena Corbic[SUP] 4 [/SUP], Leon Danon[SUP] 5 [/SUP], Katrin Dubischar[SUP] 4 [/SUP], Christopher J A Duncan[SUP] 6 [/SUP], Susanne Eder-Lingelbach[SUP] 4 [/SUP], Saul N Faust[SUP] 7 [/SUP], Christopher Green[SUP] 3 [/SUP], Karishma Gokani[SUP] 3 [/SUP], Romana Hochreiter[SUP] 4 [/SUP], Johanna Kellett Wright[SUP] 1 [/SUP], Dowan Kwon[SUP] 1 [/SUP], Alexander Middleditch[SUP] 1 [/SUP], Alasdair P S Munro[SUP] 7 [/SUP], Kush Naker[SUP] 3 [/SUP], Florentina Penciu[SUP] 1 [/SUP], David Price[SUP] 6 [/SUP], Benedicte Querton[SUP] 4 [/SUP], Tawassal Riaz[SUP] 1 [/SUP], Amy Ross-Russell[SUP] 7 [/SUP], Amada Sanchez-Gonzalez[SUP] 6 [/SUP], Hayley Wardle[SUP] 6 [/SUP], Sarah Warren[SUP] 7 [/SUP], Adam Finn[SUP] 8 [/SUP], Valneva Phase 1 Trial Group
Affiliations
- PMID: 35718205
- DOI: 10.1016/j.jinf.2022.06.009
Abstract
Objectives: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001.
Methods: We conducted an open-label, dose-escalation study followed by a double-blind randomized trial using low, medium and high doses of VLA2001 (1:1:1). The primary safety outcome was the frequency and severity of solicited local and systemic reactions within 7 days after vaccination. The primary immunogenicity outcome was the geometric mean titre of (GMT) of neutralizing antibodies against SARS-CoV-2 two weeks after the second vaccination. The study is registered as NCT04671017.
Results: Between December 16, 2020, and June 3, 2021, 153 healthy adults aged 18-55 years were recruited in the UK. Overall, 81.7% of the participants reported a solicited AE, with injection site tenderness (58.2%) and headache (46.4%) being the most frequent. Only 2 participants reported a severe solicited event. Up to day 106, 131 (85.6%) participants had reported any AE. All observed incidents were transient and non-life threatening in nature. Immunogenicity measured at 2 weeks after completion of the two-dose priming schedule, showed significantly higher GMTs of SARS-CoV-2 neutralising antibody titres in the highest dose group (GMT 545.6; 95% CI: 428.1, 695.4) which were similar to a panel of convalescent sera (GMT 526.9; 95% CI: 336.47, 825.06). Seroconversion rates of neutralising antibodies were also significantly higher in the high-dose group (>90%) compared to the other dose groups. In the high dose group, antigen-specific interferon-γ expressing T-cells reactive against the S, M and N proteins were observed in 76, 36 and 49%, respectively.
Conclusions: VLA2001 was well tolerated in all tested dose groups, and no safety signal of concern was identified. The highest dose group showed statistically significantly stronger immunogenicity with similar tolerability and safety, and was selected for phase 3 clinical development.
Keywords: COVID-19; Coronavirus; CpG 1018; RBD-binding IgG antibody; S protein binding IgG antibody; SARS-CoV-2; adjuvanted vaccine; aluminum hydroxide; inactivated vaccine; neutralizing antibody; vaccine safety; whole-virus vaccine.